Saturday 17 October 2026
Export JSPR’s income statement to Excel — free account
Jasper Therapeutics, Inc.
JSPR Healthcare Biotechnology
In the quarter to June 2026, EPS grew 94.3% and free cash flow grew 55.7%, each against the same quarter a year earlier.
0.48
0.05
−9.43%
Follow JSPR
| Dec '17 | Dec '19 | Dec '20 | Dec '21 | Dec '22 | Dec '23 | Dec '24 | Dec '25 | |
|---|---|---|---|---|---|---|---|---|
Current Ratio |
— | 13.82 | 5.16 | 10.95 | 5.91 | 7.19 | 4.98 | 2.62 |
Net Debt/EBITDA |
— | 8.90 | 0.96 | 2.32 | 0.76 | 1.28 | 0.96 | 0.35 |
Debt/Assets |
0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
Debt/Equity |
— | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Asset Turnover |
— | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Operating CF/Net income |
— | (183.75) | 0.00 | 1.10 | 1.22 | 0.81 | 0.88 | 1.02 |
Capex/Depreciation |
— | — | 0.00 | (6.44) | (0.59) | (0.24) | (0.39) | 0.00 |
| — | (0.01%) | 210.22% | (178.18%) | (71.44%) | (112.67%) | (101.73%) | (230.31%) | |
| — | 0.00% | (50.65%) | (52.37%) | (53.07%) | (90.00%) | (81.55%) | (131.06%) | |
ROIC |
— | (2.25%) | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
Return on Tangible Assets |
— | 0.14% | (182.36%) | (36.69%) | (98.56%) | (81.30%) | (114.12%) | (351.79%) |
Average Days of Receivables |
— | — | 0.00 | 0.00 | 0.00 | — | — | — |
Research and Development Expense of Revenue |
— | — | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
Selling, General and Administrative Expense of Revenue |
— | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
Intangible Assets out of Total Assets |
0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Share Based Compensation of Revenue |
— | — | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
Free Cash Flow per Share |
— | (1.47) | 0.00 | (31.69) | (12.73) | (5.01) | (4.33) | (4.03) |
Cash per Share |
— | 4.85 | 32.38 | 74.34 | 10.48 | 8.32 | 4.91 | 1.50 |
Shareholders Equity per Share |
— | 20.00 | (57.35) | 61.01 | 9.87 | 7.51 | 4.23 | 0.22 |
Interest Debt per Share |
— | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Book value per Share |
— | 20.00 | (57.35) | 61.01 | 9.87 | 7.51 | 4.23 | 0.22 |
Free Cash Flow |
— | (0.37) | 0.00 | (36.11) | (46.43) | (52.33) | (63.13) | (77.16) |
Working Capital |
— | 1.43 | 16.67 | 79.81 | 34.67 | 76.56 | 60.57 | 21.45 |
Capital Expenditures |
— | — | — | (2.43) | (0.58) | (0.27) | (0.53) | 0.01 |
Net Current Asset Value |
— | (95.15) | (37.80) | 63.70 | 29.36 | 72.49 | 57.59 | 3.02 |
| Other line items | ||||||||
Quick Ratio |
— | 10.89 | 5.09 | 10.65 | 5.51 | 7.02 | 4.70 | 2.17 |
Depreciation/Fixed assets |
— | — | 0.03 | 0.10 | 0.27 | 0.41 | 0.73 | 10.35 |
Cash ROIC |
— | (5.92%) | 0.00% | (23.41%) | (62.55%) | (31.65%) | (47.36%) | (234.92%) |
Accounts Receivable Turnover |
— | — | 0.00 | 0.00 | 0.00 | — | — | — |
Accounts Payable Turnover |
— | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Inventory Turnover |
— | — | 0.00 | 0.00 | 0.00 | — | — | — |
Average Days of Payables |
— | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Days of Inventory on Hand |
— | — | 0.00 | 0.00 | 0.00 | — | — | — |
Revenue per Share |
— | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Operating CF per Share |
— | (1.47) | 0.00 | (29.56) | (12.57) | (4.99) | (4.29) | (4.03) |
Capex per Share |
— | 0.00 | 0.00 | (2.13) | (0.16) | (0.03) | (0.04) | 0.00 |
Average Receivables |
— | — | 0.65 | 0.65 | 0.68 | — | — | — |
Average Payables |
— | 0.76 | 0.76 | 2.67 | 2.84 | 2.96 | 4.09 | 5.12 |
Average Assets |
— | 50.85 | 62.53 | 58.51 | 71.01 | 71.63 | 87.40 | 57.84 |
Average Common Equity |
— | (15.06) | (15.06) | 17.19 | 52.75 | 57.21 | 70.06 | 32.91 |
Capex to Sales |
— | — | — | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Columns are period end dates